Cargando…

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Xiaozhou, Quezada, Sergio A., Sepulveda, Manuel A., Sharma, Padmanee, Allison, James P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978270/ https://www.ncbi.nlm.nih.gov/pubmed/24687957 http://dx.doi.org/10.1084/jem.20130590

Ejemplares similares

ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4
por: Sharma, P
Publicado: (2014)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014)

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
por: Solinas, Cinzia, et al.
Publicado: (2020)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
por: Sharma, Naveen, et al.
Publicado: (2019)

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
por: Bouwhuis, Marna G., et al.
Publicado: (2009)

CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021)

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
por: Zamarin, Dmitriy, et al.
Publicado: (2017)

ICOS Regulates the Generation and Function of Human CD4(+) Treg in a CTLA-4 Dependent Manner
por: Zheng, Jian, et al.
Publicado: (2013)

Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
por: Youlin, Kuang, et al.
Publicado: (2012)

Pilot Study of Delayed ICOS/ICOS-L Blockade With αCD40 to Modulate Pathogenic Alloimmunity in a Primate Cardiac Allograft Model
por: O’Neill, Natalie A., et al.
Publicado: (2018)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2016)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
por: Ralser, Damian J., et al.
Publicado: (2023)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
por: Simpson, Tyler R., et al.
Publicado: (2013)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Differences in allergen-induced T cell activation between allergic asthma and rhinitis: Role of CD28, ICOS and CTLA-4
por: Botturi, Karine, et al.
Publicado: (2011)

Erratum to: CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2017)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

ICO investors
por: Fahlenbrach, Rüdiger, et al.
Publicado: (2020)

Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy
por: Zhao, Xiashuang, et al.
Publicado: (2023)

Colloque ICO '89
por: Moulin, B, et al.
Publicado: (1989)

Role of endocytosis and trans‐endocytosis in ICOS costimulator‐induced downmodulation of the ICOS Ligand
por: Aragoneses‐Fenoll, Laura, et al.
Publicado: (2021)

ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain
por: O’Brien, Carleigh A., et al.
Publicado: (2020)

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
por: Zhou, Yifan, et al.
Publicado: (2022)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t33kipblhlhb51gor1p4167fa4